Literature DB >> 33531028

Oligodeoxynucleotides containing unmethylated cytosine-guanine motifs are effective immunostimulants against pneumococcal meningitis in the immunocompetent and neutropenic host.

S Ribes1, L Zacke2, S Nessler2, N Saiepour2, E Avendaño-Guzmán2, M Ballüer2,3, U K Hanisch2, R Nau2,3.   

Abstract

BACKGROUND: Bacterial meningitis is a fatal disease with a mortality up to 30% and neurological sequelae in one fourth of survivors. Available vaccines do not fully protect against this lethal disease. Here, we report the protective effect of synthetic oligodeoxynucleotides containing unmethylated cytosine-guanine motifs (CpG ODN) against the most frequent form of bacterial meningitis caused by Streptococcus pneumoniae.
METHODS: Three days prior to the induction of meningitis by intracerebral injection of S. pneumoniae D39, wild-type and Toll-like receptor (TLR9)-/- mice received an intraperitoneal injection of 100 μg CpG ODN or vehicle. To render mice neutropenic, anti-Ly-6G monoclonal antibody was daily administrated starting 4 days before infection with a total of 7 injections. Kaplan-Meier survival analyses and bacteriological studies, in which mice were sacrificed 24 h and 36 h after infection, were performed.
RESULTS: Pre-treatment with 100 μg CpG ODN prolonged survival of immunocompetent and neutropenic wild-type mice but not of TLR9-/- mice. There was a trend towards lower mortality in CpG ODN-treated immunocompetent and neutropenic wild-type mice. CpG ODN caused an increase of IL-12/IL-23p40 levels in the spleen and serum in uninfected animals. The effects of CpG ODN on bacterial concentrations and development of clinical symptoms were associated with an increased number of microglia in the CNS during the early phase of infection. Elevated concentrations of IL-12/IL-23p40 and MIP-1α correlated with lower bacterial concentrations in the blood and spleen during infection.
CONCLUSIONS: Pre-conditioning with CpG ODN strengthened the resistance of neutropenic and immunocompetent mice against S. pneumoniae meningitis in the presence of TLR9. Administration of CpG ODN decreased bacterial burden in the cerebellum and reduced the degree of bacteremia. Systemic administration of CpG ODN may help to prevent or slow the progression to sepsis of bacterial CNS infections in healthy and immunocompromised individuals even after direct inoculation of bacteria into the intracranial compartments, which can occur after sinusitis, mastoiditis, open head trauma, and surgery, including placement of an external ventricular drain.

Entities:  

Keywords:  Interleukin (IL)-12/IL-23p40; Macrophage inflammatory protein (MIP)-1α; Meningitis; Microglia; Oligodeoxynucleotides containing unmethylated cytosine-guanine motifs (CpG ODN); Streptococcus pneumoniae; Toll-like receptor (TLR) 9

Year:  2021        PMID: 33531028     DOI: 10.1186/s12974-021-02077-3

Source DB:  PubMed          Journal:  J Neuroinflammation        ISSN: 1742-2094            Impact factor:   8.322


  56 in total

Review 1.  Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis.

Authors:  Karen Edmond; Andrew Clark; Viola S Korczak; Colin Sanderson; Ulla K Griffiths; Igor Rudan
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 25.071

Review 2.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 3.  Neuronal injury in bacterial meningitis: mechanisms and implications for therapy.

Authors:  Roland Nau; Wolfgang Brück
Journal:  Trends Neurosci       Date:  2002-01       Impact factor: 13.837

4.  Neuropsychological sequelae of bacterial and viral meningitis.

Authors:  H Schmidt; B Heimann; M Djukic; C Mazurek; C Fels; C-W Wallesch; R Nau
Journal:  Brain       Date:  2005-12-19       Impact factor: 13.501

5.  Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement.

Authors:  C Alexandre; F Dubos; C Courouble; I Pruvost; E Varon; A Martinot
Journal:  Acta Paediatr       Date:  2010-11       Impact factor: 2.299

Review 6.  Risk factors for community-acquired bacterial meningitis in adults.

Authors:  K S Adriani; M C Brouwer; D van de Beek
Journal:  Neth J Med       Date:  2015-02       Impact factor: 1.422

7.  Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.

Authors:  S Ben-Shimol; D Greenberg; N Givon-Lavi; Y Schlesinger; D Miron; S Aviner; R Dagan
Journal:  Vaccine       Date:  2016-07-27       Impact factor: 3.641

8.  Cognitive outcome in adults after bacterial meningitis.

Authors:  Martine Hoogman; Diederik van de Beek; Martijn Weisfelt; Jan de Gans; Ben Schmand
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-12       Impact factor: 10.154

9.  Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.

Authors:  Rebecca A Gladstone; Johanna M Jefferies; Anna S Tocheva; Kate R Beard; David Garley; Wei Wei Chong; Stephen D Bentley; Saul N Faust; Stuart C Clarke
Journal:  Vaccine       Date:  2015-03-14       Impact factor: 3.641

10.  pIgR and PECAM-1 bind to pneumococcal adhesins RrgA and PspC mediating bacterial brain invasion.

Authors:  Federico Iovino; Joo-Yeon Engelen-Lee; Matthijs Brouwer; Diederik van de Beek; Arie van der Ende; Merche Valls Seron; Peter Mellroth; Sandra Muschiol; Jan Bergstrand; Jerker Widengren; Birgitta Henriques-Normark
Journal:  J Exp Med       Date:  2017-05-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.